Drugs Containing Excipient (Inactive Ingredient) GELATIN TYPE B BOVINE

Branded drugs containing GELATIN TYPE B BOVINE excipient, and estimated key patent expiration / generic entry dates

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Mayne Pharma LLC	BIJUVA	estradiol and progesterone	50261-211	GELATIN TYPE B BOVINE	2032-11-21
Mayne Pharma	BIJUVA	estradiol and progesterone	68308-751	GELATIN TYPE B BOVINE	2032-11-21

Generic drugs containing GELATIN TYPE B BOVINE excipient

Company	Ingredient	NDC	Excipient
Teva Pharmaceuticals USA Inc	methylergonovine maleate	0093-3655	GELATIN TYPE B BOVINE
Upsher-Smith Laboratories Inc	bexarotene	0832-0285	GELATIN TYPE B BOVINE
Upsher-Smith Laboratories LLC	droxidopa	0832-0720	GELATIN TYPE B BOVINE

Gelatin Type B Bovine Excipient Market Dynamics and Financial Trajectory

Last updated: September 9, 2026

Gelatin Type B bovine is a pharmaceutical excipient used mainly in hard capsules, soft capsules, tablet binding, coating, granulation, and selected drug-delivery systems. Its commercial outlook is stable to moderately positive, supported by pharmaceutical capsule demand, biologics and nutraceutical manufacturing, and the need for validated animal-derived excipients. Profitability depends on cattle-hide availability, energy costs, bovine-origin compliance, processing yield, quality controls, and customer qualification cycles.

The market is fragmented by grade and geography. Public companies generally report gelatin within broader food, nutrition, ingredients, or collagen segments. They do not usually disclose revenue specifically for pharmaceutical-grade Type B bovine gelatin. The financial trajectory is therefore best assessed through end-market demand, input costs, production capacity, regulatory barriers, and supplier pricing power.

What is Gelatin Type B bovine and how is it manufactured?

Gelatin Type B bovine is collagen-derived gelatin produced from bovine hides or other approved bovine collagen sources through alkaline processing. The Type B designation traditionally refers to an alkaline or lime-treatment process. Type A gelatin is generally associated with acid processing, often using porcine skin.

The manufacturing sequence normally includes:

1. Selection and traceability of bovine raw material.
2. Washing, trimming, and size reduction.
3. Alkaline treatment to remove non-collagen components.
4. Extraction of gelatin with hot water.
5. Filtration, concentration, sterilization, drying, milling, and blending.
6. Testing for gel strength, viscosity, microbiological quality, ash, pH, endotoxins, and residual process-related impurities.

Pharmaceutical customers typically buy gelatin by grade rather than by broad food-grade specification. Critical attributes include Bloom strength, viscosity, particle size, moisture, microbial limits, ash, pH, color, clarity, and dissolution behavior.

Gelatin Type B bovine is selected when a customer requires bovine origin, alkaline processing, specific mechanical performance, or an alternative to porcine gelatin. It is not interchangeable with every other gelatin grade. A formulation change can require new stability, process-performance, supplier-qualification, and regulatory documentation.

What pharmaceutical products use Gelatin Type B bovine?

The principal pharmaceutical uses are hard capsules and softgel systems. Gelatin is also used as a binder or film-forming material in selected solid-dose products.

Application	Function of Type B bovine gelatin	Commercial relevance
Hard capsules	Capsule shell-forming polymer	Largest pharmaceutical use category
Soft capsules	Film-forming and elastic shell material, often with plasticizers	Important in vitamins, oils, and poorly water-soluble compounds
Tablet binding	Improves granule cohesion and tablet strength	Smaller than capsule demand
Coatings	Film formation and protection	Product-specific use
Microencapsulation	Matrix or wall material	Used in selected drug-delivery systems
Hemostatic materials	Biocompatible collagen-derived matrix	Specialized medical-device and pharmaceutical use
Vaccines and biologics	Stabilizer or processing excipient in selected products	Qualification and regulatory requirements are high
Nutraceuticals	Capsule shells and delivery matrices	Large adjacent market, but specifications differ

Hard capsules remain the most important demand driver. Gelatin capsule demand benefits from oral solid-dose launches, generic medicines, contract manufacturing, and nutraceutical consumption. Vegetarian capsule systems based on hypromellose and pullulan compete directly with animal-derived gelatin.

How large is the pharmaceutical gelatin market?

The pharmaceutical Type B bovine segment is materially smaller than the overall gelatin market and is not separately quantified in most public industry datasets. Market reports typically combine food, pharmaceutical, photographic, technical, collagen, and nutraceutical gelatin, then aggregate porcine, bovine, fish, and poultry sources.

A useful market framework is:

• Total gelatin demand is driven primarily by food and pharmaceutical capsule consumption.
• Pharmaceutical-grade material commands a premium over food-grade gelatin.
• Bovine Type B is one segment within pharmaceutical gelatin, not a standalone public reporting category.
• Supply qualification and documentation create higher switching costs than in commodity food applications.
• Capsule manufacturers and pharmaceutical companies often qualify multiple gelatin suppliers, but changing a source can require extensive comparability work.

The most relevant growth indicators are pharmaceutical capsule volumes, generic drug production, contract development and manufacturing activity, biologics stabilization requirements, and demand for animal-origin-compliant excipients.

What drives demand for Gelatin Type B bovine?

Capsule manufacturing

Capsules create recurring demand because each dosage unit consumes a small but necessary quantity of gelatin. Demand rises with prescription volume, over-the-counter products, clinical-trial manufacturing, and dietary supplements.

Capsule manufacturers including Lonza's Capsugel business, Qualicaps, ACG, and Suheung operate within the primary customer ecosystem. They may purchase gelatin directly or through qualified distributors and convert it into finished capsule shells.

Generic and contract manufacturing

Generic manufacturers use hard and soft capsules across antibiotics, proton-pump inhibitors, analgesics, cardiovascular products, central-nervous-system medicines, and specialty formulations. Contract manufacturers also support clinical and commercial products that require validated capsule materials.

Bovine-origin and market-access requirements

Bovine gelatin can be preferred where porcine-derived materials are unsuitable for religious, market, or customer reasons. It can also be selected for supply diversification. However, bovine origin introduces additional controls for bovine spongiform encephalopathy, animal sourcing, traceability, and geographic risk.

Nutraceutical demand

Nutraceuticals are a significant adjacent demand source. The segment can absorb production capacity during periods of pharmaceutical softness, but nutraceutical customers are usually more price-sensitive and may accept broader specifications. Pharmaceutical-grade suppliers therefore manage separate production, documentation, and customer-qualification channels.

Which companies supply pharmaceutical-grade bovine gelatin?

The leading supply base includes global gelatin producers and regional manufacturers. Product availability varies by site, grade, regulatory documentation, and source material.

Supplier or group	Relevant position
Gelita	Global gelatin producer with pharmaceutical and biomedical grades
Darling Ingredients / Rousselot	Major collagen and gelatin platform with pharmaceutical applications
PB Leiner	Global gelatin and collagen supplier with pharmaceutical-grade products
Nitta Gelatin	Gelatin producer with pharmaceutical and medical applications
Sterling Biotech	Bovine gelatin and collagen producer with pharmaceutical exposure
India Gelatine & Chemicals	Regional gelatin supplier serving pharmaceutical and industrial markets
Regional Asian producers	Important for cost-competitive bovine gelatin and domestic pharmaceutical supply

Supplier selection depends on the exact product grade, not only the company name. Buyers evaluate bovine origin, country of source, BSE/TSE documentation, manufacturing site, certificate of analysis, quality agreement, change-control procedures, and regulatory support.

The most defensible competitive advantage is usually manufacturing consistency and regulatory history. Patent protection is limited compared with a drug product. The main barriers are process know-how, validated facilities, supply relationships, quality systems, and customer approvals.

How strong is the patent estate for Gelatin Type B bovine?

The core gelatin molecule and the traditional Type B production concept are not generally protected by a meaningful, broad, enforceable patent estate. Gelatin has been used for decades, and basic alkaline treatment of bovine collagen is established technology.

Protection may exist around:

• Specific extraction or purification processes.
• Low-endotoxin or low-bioburden gelatin grades.
• Crosslinked gelatin matrices.
• Gelatin nanoparticles and microparticles.
• Drug-loaded gelatin implants.
• Capsule-shell compositions.
• Gelatin blends with polymers, plasticizers, or enteric materials.
• Manufacturing equipment and continuous-processing methods.
• Biomedical scaffolds and tissue-engineering compositions.

These patents usually protect a particular process, composition, dosage form, or medical use. They do not normally prevent the manufacture or sale of conventional Type B bovine gelatin that meets a pharmacopeial specification.

For investors and pharmaceutical buyers, the relevant IP risk is usually freedom to operate for a downstream formulation or delivery system, not ownership of the gelatin excipient itself.

What regulatory requirements apply to bovine gelatin?

United States

Pharmaceutical gelatin is subject to applicable FDA requirements for identity, strength, quality, purity, and suitability for intended use. The United States Pharmacopeia-National Formulary includes gelatin-related standards and general pharmaceutical quality requirements. Drug manufacturers must qualify excipient suppliers under current good manufacturing practice obligations in 21 C.F.R. Parts 210 and 211.

Bovine-origin material also requires controls addressing source animals, country of origin, traceability, contamination, and TSE risk. The regulatory file normally includes a material-origin statement, manufacturing description, specifications, analytical methods, certificates, and change-control commitments.

European Union

European pharmaceutical manufacturers generally assess gelatin under the European Pharmacopoeia and the European Medicines Agency's guidance on minimising the risk of transmitting animal spongiform encephalopathy agents through human and veterinary medicinal products. The EU also applies expectations for excipient risk assessment, good manufacturing practice, and supplier oversight.

Other markets

Japan, China, India, Brazil, and other major pharmaceutical markets apply national pharmacopoeial and animal-origin requirements. Export suppliers must manage different documentation expectations, including halal or kosher certification where relevant.

Regulatory compliance is a commercial barrier because a new supplier may require quality audits, technical agreements, stability or process comparability work, and regulatory variation filings for marketed products.

What are the main supply-chain risks?

Cattle-hide availability

Bovine gelatin producers depend on slaughter volumes, hide collection, regional sourcing, and the economics of leather production. Gelatin is often produced from by-products. Changes in cattle slaughter rates or hide prices can affect input economics.

Energy and chemical costs

Production requires hot-water extraction, concentration, drying, and wastewater treatment. Natural gas, electricity, water, alkaline chemicals, labor, and environmental compliance have a direct effect on margins.

BSE and traceability controls

BSE controls can restrict eligible raw materials and increase testing, documentation, segregation, and audit costs. A regulatory event affecting a country or supplier can disrupt qualification status even when physical supply remains available.

Geographic concentration

Production is concentrated among a limited number of global and regional manufacturers. Buyers often mitigate this exposure through dual sourcing, geographic diversification, safety stock, and pre-approved alternative grades.

Animal-origin substitution

Hypromellose and other non-animal capsule materials provide a structural substitution risk. They are especially competitive where customers require vegetarian, vegan, religiously neutral, or chemically defined excipients. Gelatin retains advantages in film formation, processing history, cost, and broad market familiarity.

What is the financial trajectory for Gelatin Type B bovine?

The financial trajectory is likely to remain stable with moderate volume growth and periodic margin volatility.

Financial driver	Expected effect
Pharmaceutical capsule demand	Supports steady volume growth
Generic-drug manufacturing	Supports recurring demand but increases price pressure
Nutraceutical demand	Adds volume but produces lower average margins
Pharmaceutical-grade qualification	Supports premium pricing and customer retention
Cattle-hide and energy costs	Creates margin volatility
Bovine compliance requirements	Raises cost but also limits new entrants
Vegetarian capsule substitution	Caps long-term growth in some applications
Supplier consolidation	Can improve pricing power for qualified producers
Capacity expansion	May pressure pricing if demand lags supply
Regulatory disruption	Can cause short-term shortages and price spikes

A supplier with a large pharmaceutical customer base can achieve more stable pricing than a producer focused on commodity food gelatin. Pharmaceutical customers value consistent quality, technical service, audit performance, and continuity of supply. Those factors support retention after qualification.

The strongest financial model is a mixed portfolio: pharmaceutical gelatin for margin and stability, nutraceutical gelatin for volume, and collagen or biomedical materials for growth. Pure exposure to pharmaceutical Type B bovine gelatin is more limited because the segment is relatively specialized and lacks transparent public revenue reporting.

When does Gelatin Type B bovine lose exclusivity?

Gelatin Type B bovine does not have a drug-like exclusivity period. It is an established excipient rather than a new molecular entity. There is no single market-wide patent expiration date, Orange Book exclusivity period, or regulatory exclusivity deadline governing its sale.

Exclusivity can arise indirectly through:

• Supplier-specific customer approvals.
• Proprietary grades.
• Contractual supply agreements.
• Confidential manufacturing know-how.
• Patents covering a particular gelatin formulation or delivery system.
• Regulatory files and quality histories that make substitution costly.

These protections are commercial rather than molecule-wide legal exclusivities.

What is the Orange Book status of Gelatin Type B bovine?

Gelatin Type B bovine is not an active pharmaceutical ingredient with an independent Orange Book listing. The FDA Orange Book lists approved drug products and related patent and exclusivity information. An excipient may be present in an approved product without receiving a standalone Orange Book entry.

As a result:

• There is no standalone Orange Book patent list for Type B bovine gelatin.
• There is no independent Paragraph IV pathway directed solely to the excipient.
• Paragraph IV litigation may arise against a finished drug product that uses gelatin in its formulation or dosage form.
• A generic applicant's challenge generally targets listed patents for the reference drug, not the gelatin raw material.

Which companies are challenging Gelatin Type B bovine suppliers?

There is no conventional Paragraph IV challenger market for the excipient itself. Competition occurs through supplier qualification, capacity additions, pricing, regional manufacturing, and substitute capsule materials.

The principal competitive threats are:

1. Existing gelatin producers offering equivalent pharmaceutical grades.
2. Regional manufacturers with lower conversion costs.
3. Capsule makers integrating backward into material supply or long-term sourcing.
4. Hypromellose and pullulan capsule suppliers.
5. Synthetic or semi-synthetic polymers in specialized delivery systems.

Litigation risk is more likely to involve supply contracts, quality disputes, trade secrets, or patents on a downstream gelatin delivery system than a direct challenge to Type B bovine gelatin as a commodity excipient.

What generic launch risks exist for products using bovine gelatin?

Generic launch risk is usually indirect. A generic applicant may use the same type of gelatin but must demonstrate that its finished product meets applicable quality, performance, and bioequivalence requirements.

Risk areas include:

• Capsule dissolution differences.
• Shell moisture and brittleness.
• Interaction with hygroscopic drug substances.
• Crosslinking during storage.
• Stability in gelatin-compatible packaging.
• Supplier changes after regulatory submission.
• BSE/TSE documentation gaps.
• Differences between bovine and porcine gelatin.
• Delays in qualifying a second supplier.

For a generic manufacturer, gelatin is rarely the primary patent barrier. It can become an operational barrier when the capsule shell affects dissolution, stability, bioequivalence, or manufacturing robustness.

How does Gelatin Type B bovine compare with hypromellose capsules?

Factor	Type B bovine gelatin	Hypromellose
Source	Animal-derived bovine collagen	Plant-derived cellulose derivative
Processing history	Long-established capsule technology	Established but formulation-specific
Consumer positioning	Conventional, animal-derived	Vegetarian and vegan compatible
Moisture behavior	Sensitive to moisture balance and crosslinking	Often preferred for some moisture-sensitive products
Cost	Often competitive at scale	Can carry a premium depending on grade
Religious certification	Requires source and process certification	Usually simpler, but certification still depends on process
Regulatory familiarity	Extensive	Extensive and growing
Substitution risk	Increasing in selected markets	Gains share where animal origin is undesirable

Gelatin generally retains an advantage in manufacturing familiarity and broad availability. Hypromellose has a stronger position in vegetarian products, certain moisture-sensitive formulations, and markets where animal-origin materials are commercially restricted.

What licensing and partnership models exist?

Licensing is more common for downstream technologies than for conventional Type B bovine gelatin. Commercial arrangements include:

• Long-term supply agreements with capsule manufacturers.
• Exclusive regional distribution.
• Co-development of low-endotoxin or biomedical grades.
• Technology licenses for gelatin nanoparticles or scaffolds.
• Contract manufacturing and private-label supply.
• Dual-source quality agreements with pharmaceutical companies.

A supplier's commercial value increases when its gelatin is embedded in a customer's validated capsule platform or approved product. This creates practical switching costs without creating formal exclusivity.

What manufacturing and IP barriers affect market entry?

Entry barriers are moderate for food gelatin and high for pharmaceutical-grade gelatin.

A new entrant must establish:

• Reliable bovine raw-material sourcing.
• Segregated and traceable supply channels.
• Validated extraction and purification processes.
• Microbiological and endotoxin control.
• Consistent gel strength and viscosity.
• Compliance with pharmacopeial specifications.
• Auditable quality systems.
• Regulatory support in major markets.
• Customer-specific technical data.
• Capacity for continuity of supply.

The barrier is strongest at the point where a supplier must move from selling material to supporting approved pharmaceutical products. A technically adequate product may still require years of customer qualification before it becomes a material commercial substitute.

Key Takeaways

• Gelatin Type B bovine is an established pharmaceutical excipient used mainly in hard capsules, softgels, and selected drug-delivery systems.
• The segment has no standalone drug-style exclusivity, Orange Book listing, or universal patent expiration date.
• Market growth is linked to capsule demand, generic drugs, contract manufacturing, and nutraceutical production.
• Public financial reporting does not isolate Type B bovine pharmaceutical gelatin revenue.
• Margins are driven by cattle-hide supply, energy, processing yield, compliance costs, and pharmaceutical-grade qualification.
• Leading supply groups include Gelita, Rousselot, PB Leiner, Nitta Gelatin, Sterling Biotech, and regional producers.
• The principal substitution threat is hypromellose and other non-animal capsule materials.
• BSE/TSE controls, traceability, supplier qualification, and manufacturing consistency are more important entry barriers than core composition patents.
• Generic launch exposure is indirect and arises mainly through capsule performance, stability, dissolution, and supplier changes.
• The most likely financial path is steady demand with moderate growth and periodic margin volatility rather than a high-growth, patent-protected expansion cycle.

FAQs

Is Gelatin Type B bovine suitable for vegetarian or vegan pharmaceuticals?

No. It is derived from bovine collagen and is not vegetarian or vegan. Hypromellose, pullulan, and selected other polymers are the principal alternatives.

Does bovine gelatin require halal or kosher certification?

Certification depends on source animals, slaughter practices, processing aids, manufacturing controls, and the certifying organization. Pharmaceutical buyers commonly request formal halal or kosher documentation when the target market requires it.

Can Type B bovine gelatin be replaced with Type A gelatin without regulatory work?

Not automatically. The two grades can differ in gel strength, viscosity, pH, ash, charge characteristics, dissolution behavior, and process performance. A change may require formulation assessment, supplier qualification, stability work, and regulatory evaluation.

Is bovine gelatin a critical raw material for capsule manufacturers?

Yes, for manufacturers that produce conventional hard or soft gelatin capsules. The material is usually managed through approved supplier lists, quality agreements, inventory controls, and, where possible, dual sourcing.

Are there biosimilar risks associated with Gelatin Type B bovine?

No direct biosimilar risk exists because gelatin is not a biologic active ingredient. Gelatin may be used as an excipient in biologic products, but any competitive risk relates to the finished biologic, formulation, or manufacturing process rather than to biosimilar status for gelatin.

References

1. European Directorate for the Quality of Medicines & HealthCare. (2024). European Pharmacopoeia. Council of Europe.

2. European Medicines Agency. (2011). Note for guidance on minimising the risk of transmitting animal spongiform encephalopathy agents via human and veterinary medicinal products (EMA/410/01 Rev. 3). European Union.

3. U.S. Food and Drug Administration. (2024). Current good manufacturing practice, quality system regulation, and related requirements for drugs: 21 C.F.R. Parts 210 and 211. U.S. Department of Health and Human Services.

4. United States Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary. United States Pharmacopeial Convention.

5. European Commission. (2015). Guidelines on the formalised risk assessment for ascertaining the appropriate good manufacturing practice for excipients of medicinal products for human use (2015/C 95/02). Official Journal of the European Union.

6. Darling Ingredients Inc. (2024). Annual report 2023. Darling Ingredients Inc.

7. Gelita AG. (2024). Pharmaceutical and biomedical gelatin product information. Gelita AG.